Articolo L’altra Medicina N. 102 – 02/2021

Bibliografia

Note e riferimenti

i https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

ii Treatments and vaccines for COVID-19 | European Medicines Agency (europa.eu)

iii AstraZeneca: EMA starts first rolling review of a COVID-19 vaccine in the EU | European Medicines Agency (europa.eu) BioNTech/Pfizer: EMA starts second rolling review of a COVID-19 vaccine | European Medicines Agency (europa.eu) Moderna: EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L. | European Medicines Agency (europa.eu)

iv https://www.trialsitenews.com/european-medicines-agency-initiates-rolling-review-of-azd1222-while-fda-puts-trial-on-hold-for-a-different-review/

v www.clinicaltrialsregister.eu

vi www.clinicaltrials.gov

viihttps://www.ema.europa.eu/en/documents/leaflet/infographic-fast-track-procedures-treatments-vaccines-covid-19_en.pdf

viii Download (1.6 MB) (who.int)

ix Pharmacovigilance plan for COVID-19 vaccines (europa.eu)

x List item EMA considerations on COVID-19 vaccine approval (PDF/205.33 KB) (new) Adopted First published: 19/11/2020 EMA/592928/2020 (europa.eu)

xi ttps://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html

xiihttps://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html

xiii Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer

xiv https://hotforsecurity.bitdefender.com/blog/leaky-pharma-giant-database-exposes-personal-information-of-us-prescription-drug-users-24386.html

xv https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy

xvihttps://www.forbes.com/sites/alexandrasternlicht/2020/05/19/scientists-raise-questions-about-moderna-vaccine-in-market-shaking-report/